key: cord-0323972-n5wfj6xz authors: Disbeschl, S.; Surgey, A. W.; Roberts, J. L.; Hendry, A.; Lewis, R.; Goulden, N.; Hoare, Z.; Williams, N.; Anthony, B. F.; Edwards, R. T.; Law, R.-J.; Hiscock, J.; Carson-Stevens, A.; Neal, R. D.; Wilkinson, C. title: Protocol for a Feasibility study incorporating a Randomised Pilot Trial with an Embedded Process Evaluation and Feasibility Economic Analysis of ThinkCancer!: A primary care intervention to expedite cancer diagnosis in Wales date: 2020-12-03 journal: nan DOI: 10.1101/2020.12.01.20241554 sha: 02291d9a49cb9d8033392310daf50b20c9d89d2d doc_id: 323972 cord_uid: n5wfj6xz Background Relative to the rest of Europe, the UK has relatively poor cancer outcomes, with late diagnosis and a slow referral process being major contributors. General practitioners (GPs) are often faced with patients presenting with a multitude of non-specific symptoms that could be cancer. Safety netting can be used to manage diagnostic uncertainty by ensuring patients with vague symptoms are appropriately monitored, which is now even more crucial due to the ongoing Covid-19 pandemic and its major impact on cancer referrals. The ThinkCancer! Workshop is an educational behaviour change intervention aimed at the whole general practice team, designed to improve primary care approaches to ensure timely diagnosis of cancer. The workshop will consist of teaching and awareness sessions, the appointment of a Safety Netting Champion and the development of a bespoke Safety Netting Plan, and has been adapted so it can be delivered remotely. This study aims to assess the feasibility of the ThinkCancer! Intervention for a future definitive randomised controlled trial. Methods The ThinkCancer! study is a randomised, multisite feasibility trial, with an embedded process evaluation and feasibility economic analysis. Twenty-three to 30 general practices will be recruited across Wales, randomised in a ratio of 2:1 of intervention versus control who will follow usual care. The workshop will be delivered by a GP educator and will be adapted iteratively throughout the trial period. Baseline practice characteristics will be collected via questionnaire. We will also collect Primary Care Intervals (PCI), Two Week Wait (2WW) referral rates, conversion rates and detection rates at baseline and six months post-randomisation. Participant feedback, researcher reflections and economic costings will be collected following each workshop. A process evaluation will assess implementation using an adapted Normalisation Measure Development (NoMAD) questionnaire and qualitative interviews. An economic feasibility analysis will inform a future economic evaluation. Discussion This study will allow us to test and further develop a novel evidenced-based complex intervention aimed at general practice teams to expedite the diagnosis of cancer in primary care. The results from this study will inform the future design of a full-scale definitive phase III trial. KEYWORDS Early cancer diagnosis, feasibility, primary care, general practitioners, safety netting, health economics, process evaluation diagnostic uncertainty by ensuring patients with vague symptoms are appropriately monitored, which is now 28 even more crucial due to the ongoing Covid-19 pandemic and its major impact on cancer referrals. The 29 ThinkCancer! Workshop is an educational behaviour change intervention aimed at the whole general practice 30 team, designed to improve primary care approaches to ensure timely diagnosis of cancer. The workshop will 31 consist of teaching and awareness sessions, the appointment of a Safety Netting Champion and the 32 development of a bespoke Safety Netting Plan, and has been adapted so it can be delivered remotely. This 33 study aims to assess the feasibility of the ThinkCancer! Intervention for a future definitive randomised 34 controlled trial. 35 The ThinkCancer! study is a randomised, multisite feasibility trial, with an embedded process evaluation and 37 feasibility economic analysis. Twenty-three to 30 general practices will be recruited across Wales, randomised 38 in a ratio of 2:1 of intervention versus control who will follow usual care. The workshop will be delivered by a 39 GP educator and will be adapted iteratively throughout the trial period. Baseline practice characteristics will be 40 collected via questionnaire. We will also collect Primary Care Intervals (PCI), Two Week Wait (2WW) referral 41 rates, conversion rates and detection rates at baseline and six months post-randomisation. Participant 42 feedback, researcher reflections and economic costings will be collected following each workshop. A process 43 evaluation will assess implementation using an adapted Normalisation Measure Development (NoMAD) 44 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint INTRODUCTION 56 Background 57 Cancer survival in the UK lags behind other western countries. 1 Referral rates and adherence to guidelines are 58 lower, 2,3 primary care providers (PCPs) are less likely to take action on potential cancer symptoms 4 and cancer 59 tends to be diagnosed at a later stage, often only after patients have presented to acute or emergency secondary 60 care services. 3 Compared with the rest of Europe, the UK has relatively low one-year survival, which could be due 61 to later diagnosis. 5 62 Timely diagnosis is key to improving cancer outcomes 6 and cancer survival. 7 Earlier diagnosis could also reduce 63 the proportion of cancer patients diagnosed through emergency care. 7 Early diagnosis is a rising priority in cancer 64 policy, 6,8 because it is cost-effective 1 and the incidence of cancer is increasing. 9 Policies in Wales emphasise the 65 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint importance of early diagnosis, and recognise that increasing demand and a slow referral process are significant 66 barriers to a quick cancer diagnosis. 3 Following the implementation of these policies, progress has been slow, 67 with late stage diagnosis continuing to be an issue. 10 68 The timely diagnosis of cancer has become even more crucial as we enter a period in which primary care and 69 cancer management has changed dramatically due to the ongoing Covid-19 pandemic. 11-13 Early figures have 70 shown a 76% decrease in urgent cancer referrals across the UK and predict a 20% increase in excess deaths for 71 patients with newly diagnosed cancers. 14 There has also been a drop in the number of patients presenting to 72 primary care 15 ; patients and clinicians may have concerns due to a perceived risk of contracting Covid-19 in a 73 healthcare setting. 14 Some patients may also attribute symptoms that could be cancer to Covid-19 and therefore, 74 may avoid health services altogether. 11, 13, 16 General practitioners (GPs) may also be reluctant to refer patients on 75 to secondary care in order to minimise infection risk. 15 The increased use of remote consultation as a result of 76 the pandemic will also have implications for the early diagnosis of cancer, as important consultation techniques 77 such as the use of visual cues and physical examination may be impacted. These issues highlight the ever-78 important need of safety netting, and Covid-related considerations will need to be made by GPs in their safety 79 netting approaches. 11 80 Primary care providers (PCPs) play a vital role in the early diagnosis of cancer. 17 A key diagnostic stage is the 81 Primary Care Interval (PCI), which is the time from first presentation to a GP with a symptom that could be cancer, 82 to the subsequent referral to a specialist in secondary care. 18 However, with an ever expanding role, PCPs are 83 presented with a plethora of non-specific symptoms, of which only a small proportion are caused by cancer, and 84 many overlap with other diseases. 6 Furthermore, with certain cancers, patients may not present with any alarm 85 symptoms 6,17 which often results in a delayed cancer diagnosis. 2 In addition, guidelines to expedite early cancer 86 diagnosis are often unclear, with great variation in strategies between different GPs. 19 87 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. In summary, it is relevant and befitting to develop and test interventions aimed at improving the quality and 103 consistency of primary care approaches to ensure timely diagnosis of cancer in the UK. This will require 104 multicomponent and complex behavioural change interventions, which utilise a multidimensional, interactive, 105 tailored, whole-practice approach. 106 The ThinkCancer! intervention is a complex behaviour change intervention aimed at general medical practice 107 teams, developed as part of the Wales Interventions for Cancer Knowledge and Early Diagnosis (WICKED) 108 research programme, described in more detail elsewhere. 28 It consists of an educational workshop that includes 109 early diagnosis and awareness sessions, evaluation of current practice-based safety netting systems and the 110 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 6 appointment of a safety netting champion. The workshop will be led by an educational facilitator who will guide 111 the development of a bespoke safety netting plan for each practice. 112 The aim of this study is to assess the feasibility of delivering the ThinkCancer! intervention and conducting a 113 future, definitive randomised controlled trial (RCT) to assess effectiveness and cost-effectiveness, in order to 114 establish whether the intervention can be rolled out in practice. 115 The objectives of this study are as follows: 117 1) To assess the feasibility of a future definitive RCT by monitoring recruitment and retention, outcome 118 measure completion and reasons for decline. 119 2) To assess the acceptability, feasibility, and utility of the ThinkCancer! intervention as a whole, and of 120 each of its individual components, and refining the intervention as necessary. 121 3) To determine the most appropriate primary outcome measure for a definitive RCT and producing means 122 and confidence intervals for calculating effect sizes for the design of a definitive trial. 123 4) To describe current contextual differences, and similarities, between general medical practices and their 124 usual safety netting practices. 125 5) To identify and test the methods and outcome measures for a process evaluation of a future definitive 126 RCT. 127 6) To undertake a feasibility analysis of the most appropriate approach for an economic evaluation 128 alongside a future definitive trial. 129 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint Study design 131 The feasibility study incorporates a pragmatic, multisite, two-armed, superiority, pilot RCT. There is an embedded 132 process evaluation and feasibility economic analysis. The unit of randomisation is the general medical practice, 133 and the primary clinical outcome is collected at the practice level. 134 The term 'feasibility' is used in accordance with the conceptual framework developed by Eldridge and 135 colleagues, 29 where it is described as an umbrella term within which pilot trials are a component. Furthermore, 136 the study has been designed in accordance with the MRC Framework for evaluating complex interventions. 30 The 137 trial will be conducted according to NIHR guidance, 31 and recommendations for good practice in pilot studies. 32 138 The process evaluation, which will be based on a mixed-methods approach, will follow the MRC guidance for 139 process evaluations of complex interventions. 33 During the initial piloting or feasibility testing stage of an 140 intervention, process evaluation has a vital role in understanding and planning the future potential 141 implementation of the intervention and optimising its design and evaluation. 33 142 The feasibility economic analysis will explore the appropriate future perspective of analysis; most appropriate 143 methods of gathering costs; range and value of outcome measures, and undertake a feasibility budget impact 144 analysis of the ThinkCancer! intervention developed through a range of blended methods that it is delivered 145 online (either in a live format or pre-recorded) or face-to-face in general practices across north Wales. 146 This study protocol was developed in line with the Standard Protocol Items: Recommendations for Interventional 147 Trials (SPIRIT) guidelines 34 ; the SPIRIT checklist (appendix 1) and the schedule of procedures can be seen in Table 148 1. The SPIRIT checklist has been adapted in accordance with the CONSORT extension to pilot and feasibility 149 trials. 35 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint Study setting 156 The setting for this study is primary care. The intervention will be delivered in-practice or online to individual 157 general medical practices and incorporates a whole-practice approach. The trial will be conducted across Wales 158 and practices will be recruited from all seven Welsh health boards. 159 The proposed intervention, the ThinkCancer! Workshop, has four chief components. The first are two 161 educational sessions, one for all clinical staff (the 'early diagnosis' session) and one for non-clinical but patient-162 facing staff (the 'cancer aware' session). The early diagnosis session is delivered as a teaching seminar with 163 learning outcomes focussed on NICE NG12 Suspected Cancer: recognition and referral guidelines 27 , hot topics 164 exploring the harder to recognise cancer presentations and consultation-level safety netting. As a proposed aid 165 to support and formalise safety netting, a new tool -the Symptom Safety Netting Action Plan (SSNAP) will be 166 introduced. This session will also see the introduction of the ThinkCancer! Handbook, which will contain all the 167 resources used in the workshop as well as external resources regarding early diagnosis and safety netting, such 168 as NICE guidance and online learning resources. The cancer aware session is less formal with more convenor-led 169 discussion around cancer red flag symptoms that non-clinical staff may encounter. The secondary aim of this 170 session is to gauge and explore issues and norms around raising concerns within the practice team. The third 171 session (the 'safety netting session') involves the two final components of the intervention, the co-production of 172 a bespoke Cancer Safety Netting Plan (CSNP) and appointment of a Cancer Safety Netting Champion (CSNC). This 173 session is attended by a combination of clinical and administrative staff who will be involved in the design and 174 implementation of a new plan. 175 Members of the research team will deliver the intervention; the GP Educator (AS) will oversee the workshop, 176 supported by up to two researchers. The workshop was originally designed to be delivered face-to-face in 177 participating practices during practices' allocated protected time for educational and professional development. 178 However, due to the ongoing Covid-19 pandemic, the workshop has been adapted into a digital format and can 179 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint be delivered in one of three ways: (i) fully remote and live via online conferencing platforms; (ii) blended delivery, 180 where practices are offered a combination of pre-recorded versions and live remote delivery of the different 181 sessions; and (iii) face-to-face in the practice, as originally intended, if the situation allows. Practices that opt for 182 the blended delivery of the workshop can choose to receive pre-recorded videos of sessions 1 and 2, presented 183 by the GP Educator, allowing participants to engage with the materials in their own time. The final session, which 184 focuses on the Cancer Safety Netting Plan, will still need to be delivered as a live session due to its interactive 185 components. There will be flexibility to work with the practice to allow the bespoke design of the workshop 186 format to improve the reach of the intervention. Practices receiving the intervention in any of the remote forms 187 will be sent all of the workshop materials, including the handbook and SSNAP tool, via post. If there is the 188 possibility to deliver the workshop face-to-face, materials will be distributed in the practice at the beginning of 189 the workshop. Practices randomised to the control group may also receive the pre-recorded videos at the end 190 of the study period, along with the intervention materials. 191 A logic model (figure 1) has been developed to describe the intervention components and how they link to the 192 intended outcomes and will be adapted throughout the study period. 193 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint A description of the excluded practices will be included to help identify potential future eligibility criteria and 202 reasons for non-participation will be sought. 203 Retention will be assessed quantitatively by the numbers of practices providing both baseline and follow up data. 204 Data on individual practice characteristics will be collected to: 205  describe the studied sample, 206  identify potential effect modifiers, 207  allow identification of 'usual practice' 208 The overarching goal of the ThinkCancer! Intervention is to change GPs' and primary care practices' behaviours 209 and systems, encouraging them to be more cancer-aware and act sooner on clinical presentations that could be 210 cancer, or more effectively safety net cases where concern exists but criteria for immediate referral are not met. 211 The proposed primary clinical outcomes for the definitive RCT relate to the early referral of suspected cancer. 212 They include the two-week wait (2WW) referral rate and the PCI. The 2WW referral rate is defined as the crude 213 rate of 2WW referrals multiplied by 100,000 and divided by practice list size. 36 The PCI is defined as the time 214 between the date of first presentation and the date of referral. 18 215 Secondary clinical outcome measures include the conversion rate and the detection rate. The conversion rate is 216 defined as the "proportion of 2WW referrals that are subsequently diagnosed with cancer" 36 and the detection 217 rate consists of the "proportion of new cancer cases treated who were referred through the Two Week Wait 218 route", 36 also known as the sensitivity. 37 These measures will allow us to further explore potential clinical 219 outcomes. 220 Although it is unlikely that we will detect a difference in the clinical measures in the feasibility study due to the 221 small sample and short duration of follow-up, we do expect these outcome measures to be affected by the 222 ongoing Covid-19 pandemic. However, the feasibility of using these outcomes will be assessed. 223 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint Feasibility of using potential clinical primary outcomes, 2WW referral rate, PCI, conversion rates and detection 224 rates, will be assessed quantitatively by determining: 225  ability to collect/capture data from the practices, based on completion rates of data collection forms 226  ability to extract relevant data from routinely collected data at Health Board level and from individual 227 practices, based on whether we are able to obtain the data via Health Board contacts and whether these 228 data are comparable with those collected by individual practices 229  suitability and variability of the data to perform as primary outcome measures for clinical effectiveness 230 Acceptance, adherence to and fidelity of the intervention will be assessed by: is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint  review relevant literature on the cost-effectiveness of online and mixed-methods Continuing 246 Professional Development (CPD) programmes for health professionals in a community setting 247  consult the DIRUM database 38 to identify the most appropriate way of capturing the costs of the 248 ThinkCancer! Intervention (online delivery and mixed-methods delivery). 249 Adaptations to the intervention and logic model will also be recorded throughout the trial period. 250 The outcome measures relating to recruitment, retention and adherence/fidelity will be assessed using RAG 252 criteria, as defined below: is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 1. Routine data. Go: data from 70% or more practices obtained; Review: data from < 70% of practices 270 obtained 271 2. Individual data. Go: data from 70% or more of individuals of each practice obtained; Review: data from 272 < 70% of individuals from each practice obtained 273 These criteria would reflect the potential outcomes for exclusion/inclusion at a full definitive trial stage rather 274 than prevention of the study progressing. 275 Sample size 276 We aim to recruit 23-30 general medical practices, depending on the ease of recruitment, using a randomisation 277 allocation ratio of 2:1 of intervention versus control. Randomising in preference to the intervention will allow us 278 to iteratively develop the intervention more effectively. 279 As this is a feasibility study, there is no requirement for a formal power calculation. This study is not intended to 280 be powered to identify a clinically meaningful difference between the intervention groups for the primary 281 outcome measures. Rather this study aims to provide robust estimates for the likely recruitment and retention 282 rates, and give an indication of the potential variability in the proposed outcome measures, which will in turn be 283 used to inform the power calculation for a future definitive RCT. This is discussed further under statistical 284 analyses. 285 286 Recruitment 287 General practices will be identified through contact details publicly available via practice websites and through 288 contact lists provided by the health boards across Wales. Practices will be invited to participate using a 289 standardised invitation via email addressed to the practice manager, along with information about the study. 290 Practice managers will be asked to consult with their team and indicate their interest in participating in the study 291 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint by responding to the email. They will also need to advise of their practice's availability for potential workshop 292 If no response to the initial email is received, a reminder email will be sent followed by a telephone call. A 294 participant flow diagram can be seen in figure 2. 295 Practices that take part in the study will be financially reimbursed for their time. We will establish contacts within 297 regional primary care clusters, with health board staff and with R&D departments in order to maximise potential 298 recruitment opportunities. The recruitment methods will be continually assessed and iteratively developed to 299 determine the most appropriate recruitment strategy for a future definitive RCT. 300 As feasibility is the main objective of this study, all types of general medical practice will be eligible for inclusion. 302 This will aid intervention refinement and allow for a better understanding of what is feasible across a range of 303 practices, and also why some practices may not be able to take part. 304 Inclusion 305 Any general practice in Wales is eligible for inclusion. The target audience for the intervention, based on a 'whole 306 team approach', includes all practice staff members. These may include, for example, GPs, nurse practitioners, 307 nurses, health care support workers (HCSWs), practice managers, administrators, receptionists or any other 308 practice staff, clinical and non-clinical. We would aim to include any new forms of primary care organisations 309 such as managed GP practice networks, or other general medical practice amalgamations, as well as traditional 310 GP partnerships. However, some of these may be unstable practices with no regular GP staff, and as such, they 311 may be difficult to recruit or find it difficult to participate. Practices participating in other research are also eligible 312 for inclusion; they will be asked to notify us of any cancer-related studies they may be participating in via the 313 baseline questionnaire. 314 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint There are no exclusion criteria. 316 Practice managers will be sent more detailed study information in the form of a 'Research Information Sheet for 318 Practices' (RISP) and a link to an online baseline practice questionnaire after they have expressed an interest to 319 take part in the study. Participating practice managers will need to indicate that they have read the study 320 information and have agreed with consent statements on the first page of the electronic questionnaire before 321 they can proceed. Prior to the commencement of the ThinkCancer! workshop, Participant Information Sheets 322 (PIS) will be provided by members of the research team and written consent will be obtained from all 323 participating members of staff. This will include consent to use anonymised data recorded on paper or audio-file 324 during workshops and workshop feedback forms. At this time point, participants will also be given the option to 325 provide their contact details should they be happy to be contacted for a telephone interview. Those who indicate 326 that they would like to take part will be contacted at least two months after the intervention. Participants from 327 practices randomised to the control arm, who do not take part in a workshop, will also have the opportunity to 328 take part in a telephone interview and will be sent an invitation letter via their practice manager. Response to 329 interview invitations and supplying of contact details will be taken as consent to be contacted and informed 330 consent will be obtained verbally at the time of interview. 331 NB Although we will initially contact practice managers, and they will most likely be the person who completes 332 the questionnaire, this task may be delegated to another member of the practice team with a particular interest 333 in the study. 334 A local practice, known to the research team, has agreed to participate in a ThinkCancer! pilot workshop prior to 336 full rollout of the feasibility study. The practice is an urban, large 12,000 patient training practice in a moderately 337 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint deprived region of North East Wales. Data will not be collected or recorded for trial purposes and feedback from 338 those participating will only be used to refine the intervention prior to its delivery across recruited practices. 339 The general medical practice will be the unit of randomisation. Randomisation will be achieved online, through 341 the remote randomisation centre at the North Wales Organisation for Randomisation Trials in Health (NWORTH) 342 at Bangor University. The randomisation system will use a dynamic adaptive allocation algorithm 39 to achieve 343 randomisation. ThinkCancer! is an open trial where blinding of participants, researchers and the statistician is 344 not possible due to the nature of the intervention and 2:1 ratio for randomisation. 345 Practices (and individuals within a practice) will be free to withdraw from the trial at any time, and their right to 347 refuse participation will be respected throughout. We will seek to understand their reasons where possible. In 348 terms of the primary outcome measures, as long as it is possible to collect the data, intention-to-treat analysis 349 will be utilised, whether or not the intervention was received or adhered to. 350 The feasibility study will be used to rehearse data collection approaches and assess their ease of use. Data will 352 be collected at time-points specific to each item and depending on the type of data. All data collected in this 353 study will be anonymised. 354 Data relating to the proposed primary outcomes for the future definitive RCT will be collected at baseline and 6 356 months after randomisation. Two week wait referral data and PCI data will be collected directly from 357 participating practices via Case Report Forms containing full instructions on how to extract the data from practice 358 IT systems. We will work with the Practice Manager, CSNC or other delegated individuals to achieve this. It is 359 recognised that this is likely to be too short a follow-up period for meaningful differences to be observed, but 360 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint the main purpose in this case will be to test the feasibility of collecting the data in this way. Additionally, we will 361 explore the availability of 2WW data at health board level. 362 The baseline and endline practice questionnaires will be available online to both intervention and control 364 practices and are to be filled out by the practice manager or other designated person, ideally in collaboration 365 with the practice team; SurveyMonkey™ will be the most likely platform. The questionnaires will consist of closed 366 questions and some open, free-text questions, and will be used to collect data for each individual practice on the 367 practice characteristics and current systems, and existing practice systems relating to cancer diagnosis and safety 368 netting. The baseline data may be used to inform some workshop planning -i.e. workshop content and delivery 369 may be tailored to some extent to suit individual practice needs and circumstances. Further process evaluation 370 data will also be collected from the practice questionnaires as they will incorporate questions exploring 371 contextual factors known to influence the success of quality improvement approaches used to improve health 372 care. 40 The baseline questionnaire will be completed by all practices prior to randomisation. The endline 373 questionnaire will assess any differences in practice, knowledge or systems in comparison with those measured 374 at baseline and will be completed at 6 months post-randomisation. 375 Baseline measures will include the following: 376 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. Recruitment, retention and questionnaire completion numbers will be recorded throughout the trial. 390 Spreadsheet systems will be put in place to record practice responses and to track their progress in the trial (e.g. 391 number of practices approached, whether they have responded to the initial invitation, whether they have 392 agreed to be randomised, etc.). Separate spreadsheets will also record feasibility data relating to the workshop 393 itself, such as participant numbers. 394 Data specific to the intervention will be collected via participant feedback and observation and reflections of the 396 research staff. Participant feedback forms will be distributed to practice staff; these can be completed in paper 397 format or online. Responses will be requested using a combination of Yes/No choices, Likert scales and free-text 398 comments. The questions will cover a number of areas including acceptability, usefulness, learning outcomes 399 and the potential to change practice. 41 400 Relevant ad hoc communications with practices throughout the study will also be collected on a spreadsheet, 401 which may contribute to understanding the intervention in terms of what works, why and how. 402 The same research team members will deliver the intervention in all practices; their observations will be 403 collected and will inform any refinements of the intervention. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 20 The researchers will keep a diary, which will include a record of any modifications made to the intervention and 409 data collection methods. 410 Health economics data collection sheets will be completed by the researchers following each workshop, and 412 costings specific to the practice will be recorded. We will also use the feedback forms to determine staff roles 413 within the practice for costing purposes. 414 At least two months after the intervention, participants who consented to be contacted will be sent a link to 416 complete an adapted Normalisation Measure Development (NoMAD) instrument. 42 This will assess the 417 implementation of the cancer safety netting plan using Normalization Process Theory (NPT) principles, which 418 may or may not include the SSNAP tool depending on uptake. 419 We will conduct qualitative telephone interviews lasting up to 30 minutes with a purposive sample of up to 45 421 clinical and non-clinical practice staff. Practice staff in both arms of the trial will be eligible to participate in the 422 interviews as they will be invited to give feedback on all aspects of the trial process including the intervention 423 where appropriate. The qualitative interviews are designed to achieve an in-depth understanding of the views 424 and perceptions of practice staff involved in the trial. The interviews will allow participants to explain how they 425 were able to utilise aspects of the trial and how they worked in practice. Informed consent will be obtained and 426 interviews recorded and transcribed verbatim. The interviews will be semi-structured and will follow a pre-427 defined topic guide, although not every participant will be engaged with every section of the topic guide (i.e. 428 only the specific areas of the topic guide that are relevant to an individual's role and experience will be explored). 429 Topics may include acceptability, safety netting, data collection, uptake of the intervention and SSNAP tool and 430 implications. These interviews will occur at least two months after the intervention has taken place; control 431 practices will be invited two months post-randomisation. 432 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint A risk assessment has found this trial to be low risk. Non-serious adverse events will not be collected. However, 434 Serious Adverse Events (SAEs) will be reported that could be related to the intervention, as decided by the Chief 435 Investigator (CI), and in line with current ICH-GCP Standard Operating Procedures. 43 SAEs are defined as follows: 436 "…an untoward occurrence that (a) results in death; (b) is life-threatening; (c) requires hospitalisation; 437 (d) results in persistent or significant disability or incapacity; (e) consists of a congenital anomaly or birth 438 defect; or (f) is otherwise considered medically significant by the investigator" 43 439 We do not expect any related SAEs for this study. 440 A fully documented statistical analysis plan will be prepared by a registered trials unit and agreed by the co-443 investigators and approved by the trial governance structure, which will be known as the Trial Steering 444 Committee (TSC). 445 Baseline characteristics will be summarised for all practices, the intervention group and control groups 446 separately. Feasibility and process evaluation data such as practice recruitment rate, implementation and uptake 447 of and adherence to the intervention, and follow-up rates will be summarised and presented as percentages. 448 Determining differences in clinical outcomes between the control and intervention is not the primary purpose 449 of this study, therefore the focus of the results will be on the estimates of the treatment effects rather than 450 statistical significance and as such, no hypothesis testing will be undertaken. As recommended in guidelines for 451 good practice for the analysis of pilot studies, 32 summary estimates of effects will be developed along with their 452 95% confidence intervals. Differences between the two comparison groups will be presented in the form of an 453 unadjusted mean difference for continuous outcomes, and an odds ratio for binary outcomes. Exploratory 454 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 22 analysis using ANCOVA for continuous outcomes and logistic regression for binary outcomes will consider 455 adjustment for the stratification variables in assessment of the treatment effects. 456 Factors associated with the ability to implement the intervention will be tentatively explored using logistic 457 regression with the focus on identifying deterministic barriers to implementation rather than probabilistic 458 factors. The nature of the intervention may vary, directed by real-time feedback during the course of the trial 459 and this will need to be taken into consideration during analysis. 460 As this is a feasibility study, there will be no imputation of missing data over and above any scoring rules 461 established for the outcomes. This information will be used to feed into the suitability and applicability of the 462 chosen outcome measures. 463 Alongside the statistical analysis plan, a Health Economics Analysis Plan (HEAP) will be produced setting out the 465 objectives, methods and plans for dissemination of the health economics findings. 44 The transcribed telephone interviews, the free text responses from the feedback forms and the observational 477 data, in text form, will be analysed for the process evaluation using Framework Analysis. 45 Framework is a five-478 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 23 stage matrix-based system for analysing qualitative data which is highly appropriate for a feasibility study which 479 is iterative in its development. Initially all transcripts and textual data will be read thoroughly by the same 480 researcher who conducted the interviews to achieve data familiarisation and immersion. An index of emergent 481 themes will then be created and data coded according to the index. Charts will be created according to the 482 themes and coded data will be synthesised into the appropriate thematic charts. The completed charts will then 483 be used for final stage which is in-depth interpretation. 45 484 485 The Sponsor is Bangor University. The study will be supported by the North Wales Organisation for Randomised 487 Trials in Health (NWORTH), which is a fully registered Clinical Trials Unit. 488 There will be no on-site monitoring as there are no local research teams at sites. Therefore, the monitoring of 489 data will have a more internal focus in the form of self-audits to ensure compliance with regulations. 490 The operational working group will be responsible for the overall conduct, supervision and progress of the study. 493 They consist of the immediate research team, supported by a wider group of experts. 494 The Trial Management group (TMG) will meet once a month, consisting of the operational group and a wider 496 team of experts, including a PPI member. The group will be responsible for the overall management of the trial, 497 and ensuring the study adheres to the protocol. 498 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint Trial Governance Structure 499 A Trial Steering Committee (TSC) committee will provide independent oversight for the study, ensuring it is 500 conducted according to the standards set out by the HRA Research Governance Framework. 46 As the study 501 includes an element of ongoing intervention refinement, and is deemed low risk with very minimal likelihood of 502 stopping early due to patient safety, a Data Monitoring and Ethics Committee (DMEC) will not be required. 47 503 Meetings are expected to be biannual and the Sponsor and Funder will be updated following each meeting. The 504 TSC will have an independent chairperson and at least three independent members including Patient and Public 505 Involvement (PPI) representation, trial co-applicants, statisticians, health economist(s) and GPs. 506 A detailed data management plan will be written by NWORTH staff. This plan will include the definition of the 508 data quality checks that will be performed on the data throughout the life course of the trial. These will include 509 source data validation, random data checks and timelines for data entry. All investigators, trial site and research staff will comply with the requirements and regulations of the EU General 516 Data Protection Regulation 2018 (GDPR) regarding the collection, storage, processing and disclosure of personal 517 information and will uphold the Regulation's core principles. All research staff involved will have up to date GCP 518 training. Research data will be retained as per the Sponsor's research data management policy. Bangor University 519 is the data custodian. 520 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint As per the Sponsor's research data management policy, research data and records will be archived along with 522 the data management policy of the Sponsor. 523 In line with legal requirements, trial documents will be archived centrally at a secure facility with appropriate 524 environmental controls and adequate protection from fire, flood and unauthorized access. Archived material will 525 be stored in tamper-proof archive boxes that are clearly labelled. Electronic archiving will be provided by the 526 Sponsor for post-project deposit and retention of data. 527 Destruction of essential documents will require authorisation from the Sponsor. 528 529 On completion of the study a final report will be prepared for Cancer Research Wales. 530 Findings will be disseminated through various media, including open-access peer-reviewed publications, national 531 and international conferences, the programme web pages, social media, and through an end-of-programme 532 symposium for key stakeholders. Findings will also be disseminated to participating practice teams. The study team recognises that the involvement of those with lived experiences will be vital in this research. 539 Furthermore, a lay perspective is essential in the development and undertaking of research for the promotion of 540 equality, diversity and transparency. Two patient representatives were initially recruited to the WICKED 541 programme, one of whom has maintained active involvement in the study design, the development of the 542 protocol and conduct throughout. Additionally, the trial PPI has been active in providing feedback on participant-543 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. Diagnosis (WICKED). The intervention will consist of a workshop aimed at the entire general practice team, as 551 previous work packages have demonstrated the value of a whole-practice approach. If the intervention is shown 552 to be feasible, we will proceed with designing a full-scale definitive trial. 553 This trial is especially relevant due to the current ongoing Covid-19 pandemic, which has had a major negative 554 impact on suspected cancer referrals to secondary care, and will likely delay many cancer diagnoses and 555 treatments, leading to poorer patient outcomes. One of the key strengths of this intervention is that it can be 556 iteratively developed throughout the study period, which will ensure the future definitive trial will adopt an 557 optimal approach. The design process of the study is also a strength in that a strong multidisciplinary team and 558 advisory groups have been involved throughout. Furthermore, the mixed methods approach will allow us to 559 capture a variety of data from this complex intervention. Furthermore, the planned rigour with which the study 560 will be conducted is also a strength. 561 We are aware that some challenges in the recruitment lay ahead, but we plan to work with the various 562 research infrastructures in Wales to overcome this. We plan to work closely with the Primary Care Specialty 563 Lead and Primary Care Research Managers within Health and Care Research Wales, as well as with the 564 individual health board R&D departments in order to maximise recruitment. We will also work closely with the 565 practices that agree to take part in order to support their participation in the study. 566 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 27 Although safety-netting has garnered more attention in recent years, there currently are no recommendations 567 on how best to do it. 26 To our knowledge, there are no interventions targeting primary care with a focus on 568 safety netting. In addition, involving the entire practice is a relatively novel approach, with great potential 569 benefit. This study encompasses a multicomponent and complex behavioural change intervention comprising a 570 multidimensional, interactive, tailored and whole-practice approach, which is timely and needed to optimise 571 primary care approaches to the timely diagnosis of cancer. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint Cancer Research UK position paper: The diagnostic workforce in Wales International variation in adherence to 692 referral guidelines for suspected cancer: a secondary analysis of survey data Wales Cancer Network. Cancer Delivery Plan for Wales Explaining variation in cancer 697 survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care 698 vignette survey The International Cancer Benchmarking 700 Partnership: an international collaboration to inform cancer policy in The expanding role of primary care 703 in cancer control Improving early diagnosis of symptomatic cancer Symptom signatures and diagnostic timeliness 707 in cancer patients: A review of current evidence Key statistics Diagnostic routes and time intervals 711 for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from 712 the International Cancer Benchmarking Partnership (ICBP) Impact of the COVID-19 pandemic on the 714 symptomatic diagnosis of cancer: the view from primary care Risky Business: lessons from covid-19 Provision of cancer care during the COVID-19 pandemic Estimating excess mortality in 719 people with cancer and multimorbidity in the COVID-19 emergency How coronavirus is impacting cancer services in the UK Covid-19: Cancer mortality could rise at least 20% because of pandemic, study finds Primary care and cancer: Facing the challenge of early diagnosis and survivorship The Aarhus Statement: improving design 730 and reporting of studies on early cancer diagnosis GPs' understanding and practice of 732 safety netting for potential cancer Interventions to reduce primary care delay in cancer referral: a 734 systematic review Systematic review and meta-analysis of practice facilitation within primary 736 care settings Educational interventions for primary healthcare professsionals to promote 738 the early diagnosis of cancer: a systematic review Referral interventions from primary to 740 specialist care: a systematic review of international evidence Can safety-netting improve cancer detection in patients with vague 743 symptoms? Impact of investigations in general 745 practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary 746 care audit data Safety netting for primary care: evidence from a literature review Suspected cancer: recognition and referral (NG12) Development of an intervention to 752 expedite early cancer diagnosis through primary care Defining feasibility and pilot 754 studies in preparation for randomised controlled trials: development of a conceptual framework Developing and evaluating complex 757 interventions: the new Medical Research Council guidance NIHR Research for Patient Benefit (RfPB) Programme Guidance on Applying for Feasibility Studies Design and analysis of pilot studies: recommendations for good practice Process evaluation of complex 764 interventions Statement: 767 Defining standard protocol items for clinical trials statement: 769 extension to randomised pilot and feasibility trials General Practice Profiles for cancer: Meta-data for profile indicators Variation in use of the 2-week referral 775 pathway for suspected cancer: a cross-sectional analysis. The British journal of general practice : the journal of 776 the Database of Instruments for Resource Use Measurement Generalized method for adaptive randomization in 780 clinical trials The Model for Understanding Success in Quality (MUSIQ): 782 building a theory of context in healthcare quality improvement The Kirkpatrick Model The Normalization Process Theory On-Line User's Manual, Toolkit and NoMAD instrument Resource Use Measure: Expert Delphi Consensus Survey Qualitative 792 Research Practice. A guide for social science students and researchers London UK Framework for Health and Social Care Research is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 29 Participants are consented at two different time points in the study. Practice managers will consent to 611 participate in the study on behalf of the general medical practice. If the practice has been randomised to the 612 intervention, individual staff participants will be asked for their informed consent at the start of the workshop. 613 Bangor University. The Sponsor had no role in the design of this trial and will not have any role during its 615 execution, analyses, data interpretation or decision to submit results. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint 31 AH is the qualitative researcher for the study and contributed to the protocol via the embedded qualitative 655 component and design of qualitative data collection materials. AH also contributed to gaining R&D approvals 656 from the seven health boards. AH also read and approved the final manuscript. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 3, 2020. ; https://doi.org/10.1101/2020.12.01.20241554 doi: medRxiv preprint